DD's MemCor MBR System Chosen for Major Plant Upgrade in Australia

DuPont de Nemours, Inc. DD recently announced that its MemCor membrane bioreactor (“MBR”) system has been selected for the expansion of the treatment facility at the Lower Molonglo Water Quality Control Center (“LMWQCC”) in Canberra, Australia. The project will help the facility address rising wastewater treatment demand driven by population growth.

The LMWQCC, owned and operated by Icon Water, is the largest inland wastewater treatment facility in Australia and has been operational since the late 1970s. As part of its major upgrade in collaboration with Seymour Whyte and VINCI Construction Grands Projects, the facility will add a new secondary treatment process based on advanced membrane technology.

DuPont’s MemCor MBR system will provide a treatment capacity of approximately 97 million liters per day, enabling the facility to support Canberra’s requirements. The system will also be manufactured in Australia, highlighting DuPont’s ability to combine global technology with local expertise.

The selection strengthens DuPont’s position in the market, where demand for efficient and scalable solutions is increasing alongside population growth and infrastructure investment. MemCor MBR systems, along with MemPulse modules, have been deployed across hundreds of municipal and industrial installations worldwide, building a high reputation based on high reliability.

DuPont’s Water Solutions portfolio includes membranes, resins and complete treatment systems serving municipalities, desalination plants and industrial users across 112 countries. The project further demonstrates the company’s role in addressing growing global water-treatment needs.

DD’s shares have lost 33.4% over the past year against the industry’s 7.4% rise.

Image Source: Zacks Investment Research

DD’s Zacks Rank & Key Picks

DD currently carries a Zacks Rank #3 (Hold). 

Some better-ranked stocks in the Basic Materials space are Neo Performance Materials Inc. NOPMF, Carpenter Technology Corporation CRS and Avient Corporation AVNT.

While NOPMF currently sports a Zacks Rank #1 (Strong Buy), CRS and AVNT carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for NOPMF’s 2026 earnings is pinned at $1.48 per share, indicating a 202.04% year-over-year increase. NOPMF’s shares have gained 113.7% over the past year.

The Zacks Consensus Estimate for CRS’ fiscal 2027 earnings is pegged at $12.92 per share, indicating a rise of 20.07% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.39%.

The Zacks Consensus Estimate for AVNT’s current-year earnings is pinned at $3.17 per share, indicating a 12.41% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 3.4%. AVNT’s shares have gained 29.5% over the past year.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research